Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/24/2018
/ Appropriations Bill ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Budget ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Legislative Committees ,
Medicaid ,
Medicare ,
Medicare Access and CHIP Reauthorization (MACRA) ,
Opioid ,
Secretary of HHS ,
Stark Law ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/16/2018
/ Affordable Care Act ,
Appropriations Bill ,
Association Health Plans ,
Centers for Medicare & Medicaid Services (CMS) ,
DEA ,
Department of Education ,
Department of Health and Human Services (HHS) ,
Department of Labor (DOL) ,
Electronic Health Record Incentives ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Funding Opportunities ,
GAO ,
Health Insurance ,
Health Savings Accounts ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Medicare Advantage ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Proposed Regulation ,
Section 340B ,
Telemedicine
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/26/2018
/ Affordable Care Act ,
Agency Consolidation ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
SAMHSA ,
Stark Law ,
State and Local Government ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more
5/21/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration